AKBA - Akebia Therapeutics: Post-Earnings Dip Looks Like A Discounted Entry Ahead Of A Vafseo Inflection
2025-08-28 08:17:12 ET
Thesis
At $3.13 a share, I’m pretty bullish on Akebia ( AKBA ) stock. The 21% sell-off after Q2 earnings looks more like an overreaction than a red flag to me. Sure, the EPS quality wasn’t perfect, but the growth was undeniable, and Vafseo’s ramp is just starting to kick in in my eyes. I see the dip as a chance to pick up the stock at a discount right before the DaVita pilot and other dialysis chain partnerships start translating into some real revenue. For a name that’s shifting from a speculative biotech into a commercial company with a growing sales base, buying into that transition story at just over $3 feels like solid risk/reward. Take a look at the 3-month chart below. Akebia, for a long time, was heavily outperforming the S&P until the last earnings call. Share prices are yet to recover. I don't feel that a bad earnings derail Akebia from the growth trajectory it was on. I only see the expectations for a more reliable revenue source delayed. ...
Akebia Therapeutics: Post-Earnings Dip Looks Like A Discounted Entry Ahead Of A Vafseo Inflection